Spectrum and clinical significance of autoantibodies against transfer RNA

Yasuo Ohosone, Mutsuko Ishida, Yoshiko Takahashi, Mami Matsumura, Michito Hirakata, Yoshie Kawahara, Takeji Nishikawa, Tsuneyo Mimori

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective. To characterize the clinical features of patients who have autoantibodies against transfer RNA (tRNA) or tRNA-associated proteins. Methods. Sera from 1,472 patients with suspected systemic rheumatic disease were screened by RNA immunoprecipitation of HeLa cell extracts. The specificities of the antibodies that precipitated tRNAs were further analyzed by immunoprecipitation using deproteinized RNAs and 35S-methionine-labeled HeLa cell extracts, followed by immunoblotting. Results. Forty-one serum samples (2.8%) were found to immunoprecipitate tRNAs. Thirteen patients were identified as having previously defined antiaminoacyl-tRNA synthetase antibodies (anti-histidyl-tRNA synthetase in 4 patients, anti-threonyl-tRNA synthetase in 1, anti-alanyl-tRNA synthetase in 3, antiglycyl-tRNA synthetase in 4, and anti-isoleucyl-tRNA synthetase in 1). All 13 patients had myositis and/or interstitial pneumonitis. Sera from the remaining 28 patients immunoprecipitated previously unidentified tRNAs, including 13 serum samples that bound deproteinized cognate tRNA; 24 of the 28 patients met criteria for either systemic lupus erythematosus (SLE) or Sjogren's syndrome (SS). In addition, nonerosive polyarthritis, leukocytopenia, rheumatoid factor, and characteristic annular or papulosquamous recurrent erythema were noted in these patients; however, renal involvement was rare. Sera from 16 of these 28 patients also contained anti-Ro/SSA and/or anti-La/SSB antibodies. While 189 patient sera precipitated Ro/SSA and/or La/SSB-associated RNAs but not tRNA, only 12 of the patients (6.3%) developed skin lesions (P = 0.0009, odds ratio 8.85). Conclusion. Novel autoantibodies against tRNAs or tRNA-associated proteins were identified in 28 sera. These autoantibodies appear to be distinct from antiaminoacyl-tRNA synthetase antibodies and are associated with SLE and SS. The presence of anti-Ro/SSA and/or anti-La/SSB along with anti-tRNA antibodies is more strongly associated with recurrent erythema than is the presence of anti-Ro/SSA or anti-La/SSB alone.

Original languageEnglish
Pages (from-to)1625-1631
Number of pages7
JournalArthritis and Rheumatism
Volume41
Issue number9
DOIs
Publication statusPublished - 1998 Sep

Fingerprint

Transfer RNA
Autoantibodies
Amino Acyl-tRNA Synthetases
Serum
Sjogren's Syndrome
RNA
Erythema
Cell Extracts
HeLa Cells
Immunoprecipitation
Systemic Lupus Erythematosus
Antibodies
Myositis
Antibody Specificity
Rheumatoid Factor
Interstitial Lung Diseases
Leukopenia
Rheumatic Diseases
Immunoblotting
Methionine

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Spectrum and clinical significance of autoantibodies against transfer RNA. / Ohosone, Yasuo; Ishida, Mutsuko; Takahashi, Yoshiko; Matsumura, Mami; Hirakata, Michito; Kawahara, Yoshie; Nishikawa, Takeji; Mimori, Tsuneyo.

In: Arthritis and Rheumatism, Vol. 41, No. 9, 09.1998, p. 1625-1631.

Research output: Contribution to journalArticle

Ohosone, Y, Ishida, M, Takahashi, Y, Matsumura, M, Hirakata, M, Kawahara, Y, Nishikawa, T & Mimori, T 1998, 'Spectrum and clinical significance of autoantibodies against transfer RNA', Arthritis and Rheumatism, vol. 41, no. 9, pp. 1625-1631. https://doi.org/10.1002/1529-0131(199809)41:9<1625::AID-ART13>3.0.CO;2-D
Ohosone, Yasuo ; Ishida, Mutsuko ; Takahashi, Yoshiko ; Matsumura, Mami ; Hirakata, Michito ; Kawahara, Yoshie ; Nishikawa, Takeji ; Mimori, Tsuneyo. / Spectrum and clinical significance of autoantibodies against transfer RNA. In: Arthritis and Rheumatism. 1998 ; Vol. 41, No. 9. pp. 1625-1631.
@article{d364357bf18e43349356260e43647efc,
title = "Spectrum and clinical significance of autoantibodies against transfer RNA",
abstract = "Objective. To characterize the clinical features of patients who have autoantibodies against transfer RNA (tRNA) or tRNA-associated proteins. Methods. Sera from 1,472 patients with suspected systemic rheumatic disease were screened by RNA immunoprecipitation of HeLa cell extracts. The specificities of the antibodies that precipitated tRNAs were further analyzed by immunoprecipitation using deproteinized RNAs and 35S-methionine-labeled HeLa cell extracts, followed by immunoblotting. Results. Forty-one serum samples (2.8{\%}) were found to immunoprecipitate tRNAs. Thirteen patients were identified as having previously defined antiaminoacyl-tRNA synthetase antibodies (anti-histidyl-tRNA synthetase in 4 patients, anti-threonyl-tRNA synthetase in 1, anti-alanyl-tRNA synthetase in 3, antiglycyl-tRNA synthetase in 4, and anti-isoleucyl-tRNA synthetase in 1). All 13 patients had myositis and/or interstitial pneumonitis. Sera from the remaining 28 patients immunoprecipitated previously unidentified tRNAs, including 13 serum samples that bound deproteinized cognate tRNA; 24 of the 28 patients met criteria for either systemic lupus erythematosus (SLE) or Sjogren's syndrome (SS). In addition, nonerosive polyarthritis, leukocytopenia, rheumatoid factor, and characteristic annular or papulosquamous recurrent erythema were noted in these patients; however, renal involvement was rare. Sera from 16 of these 28 patients also contained anti-Ro/SSA and/or anti-La/SSB antibodies. While 189 patient sera precipitated Ro/SSA and/or La/SSB-associated RNAs but not tRNA, only 12 of the patients (6.3{\%}) developed skin lesions (P = 0.0009, odds ratio 8.85). Conclusion. Novel autoantibodies against tRNAs or tRNA-associated proteins were identified in 28 sera. These autoantibodies appear to be distinct from antiaminoacyl-tRNA synthetase antibodies and are associated with SLE and SS. The presence of anti-Ro/SSA and/or anti-La/SSB along with anti-tRNA antibodies is more strongly associated with recurrent erythema than is the presence of anti-Ro/SSA or anti-La/SSB alone.",
author = "Yasuo Ohosone and Mutsuko Ishida and Yoshiko Takahashi and Mami Matsumura and Michito Hirakata and Yoshie Kawahara and Takeji Nishikawa and Tsuneyo Mimori",
year = "1998",
month = "9",
doi = "10.1002/1529-0131(199809)41:9<1625::AID-ART13>3.0.CO;2-D",
language = "English",
volume = "41",
pages = "1625--1631",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Spectrum and clinical significance of autoantibodies against transfer RNA

AU - Ohosone, Yasuo

AU - Ishida, Mutsuko

AU - Takahashi, Yoshiko

AU - Matsumura, Mami

AU - Hirakata, Michito

AU - Kawahara, Yoshie

AU - Nishikawa, Takeji

AU - Mimori, Tsuneyo

PY - 1998/9

Y1 - 1998/9

N2 - Objective. To characterize the clinical features of patients who have autoantibodies against transfer RNA (tRNA) or tRNA-associated proteins. Methods. Sera from 1,472 patients with suspected systemic rheumatic disease were screened by RNA immunoprecipitation of HeLa cell extracts. The specificities of the antibodies that precipitated tRNAs were further analyzed by immunoprecipitation using deproteinized RNAs and 35S-methionine-labeled HeLa cell extracts, followed by immunoblotting. Results. Forty-one serum samples (2.8%) were found to immunoprecipitate tRNAs. Thirteen patients were identified as having previously defined antiaminoacyl-tRNA synthetase antibodies (anti-histidyl-tRNA synthetase in 4 patients, anti-threonyl-tRNA synthetase in 1, anti-alanyl-tRNA synthetase in 3, antiglycyl-tRNA synthetase in 4, and anti-isoleucyl-tRNA synthetase in 1). All 13 patients had myositis and/or interstitial pneumonitis. Sera from the remaining 28 patients immunoprecipitated previously unidentified tRNAs, including 13 serum samples that bound deproteinized cognate tRNA; 24 of the 28 patients met criteria for either systemic lupus erythematosus (SLE) or Sjogren's syndrome (SS). In addition, nonerosive polyarthritis, leukocytopenia, rheumatoid factor, and characteristic annular or papulosquamous recurrent erythema were noted in these patients; however, renal involvement was rare. Sera from 16 of these 28 patients also contained anti-Ro/SSA and/or anti-La/SSB antibodies. While 189 patient sera precipitated Ro/SSA and/or La/SSB-associated RNAs but not tRNA, only 12 of the patients (6.3%) developed skin lesions (P = 0.0009, odds ratio 8.85). Conclusion. Novel autoantibodies against tRNAs or tRNA-associated proteins were identified in 28 sera. These autoantibodies appear to be distinct from antiaminoacyl-tRNA synthetase antibodies and are associated with SLE and SS. The presence of anti-Ro/SSA and/or anti-La/SSB along with anti-tRNA antibodies is more strongly associated with recurrent erythema than is the presence of anti-Ro/SSA or anti-La/SSB alone.

AB - Objective. To characterize the clinical features of patients who have autoantibodies against transfer RNA (tRNA) or tRNA-associated proteins. Methods. Sera from 1,472 patients with suspected systemic rheumatic disease were screened by RNA immunoprecipitation of HeLa cell extracts. The specificities of the antibodies that precipitated tRNAs were further analyzed by immunoprecipitation using deproteinized RNAs and 35S-methionine-labeled HeLa cell extracts, followed by immunoblotting. Results. Forty-one serum samples (2.8%) were found to immunoprecipitate tRNAs. Thirteen patients were identified as having previously defined antiaminoacyl-tRNA synthetase antibodies (anti-histidyl-tRNA synthetase in 4 patients, anti-threonyl-tRNA synthetase in 1, anti-alanyl-tRNA synthetase in 3, antiglycyl-tRNA synthetase in 4, and anti-isoleucyl-tRNA synthetase in 1). All 13 patients had myositis and/or interstitial pneumonitis. Sera from the remaining 28 patients immunoprecipitated previously unidentified tRNAs, including 13 serum samples that bound deproteinized cognate tRNA; 24 of the 28 patients met criteria for either systemic lupus erythematosus (SLE) or Sjogren's syndrome (SS). In addition, nonerosive polyarthritis, leukocytopenia, rheumatoid factor, and characteristic annular or papulosquamous recurrent erythema were noted in these patients; however, renal involvement was rare. Sera from 16 of these 28 patients also contained anti-Ro/SSA and/or anti-La/SSB antibodies. While 189 patient sera precipitated Ro/SSA and/or La/SSB-associated RNAs but not tRNA, only 12 of the patients (6.3%) developed skin lesions (P = 0.0009, odds ratio 8.85). Conclusion. Novel autoantibodies against tRNAs or tRNA-associated proteins were identified in 28 sera. These autoantibodies appear to be distinct from antiaminoacyl-tRNA synthetase antibodies and are associated with SLE and SS. The presence of anti-Ro/SSA and/or anti-La/SSB along with anti-tRNA antibodies is more strongly associated with recurrent erythema than is the presence of anti-Ro/SSA or anti-La/SSB alone.

UR - http://www.scopus.com/inward/record.url?scp=0031684343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031684343&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(199809)41:9<1625::AID-ART13>3.0.CO;2-D

DO - 10.1002/1529-0131(199809)41:9<1625::AID-ART13>3.0.CO;2-D

M3 - Article

C2 - 9751095

AN - SCOPUS:0031684343

VL - 41

SP - 1625

EP - 1631

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 9

ER -